<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297788</url>
  </required_header>
  <id_info>
    <org_study_id>S-470/2017</org_study_id>
    <nct_id>NCT03297788</nct_id>
  </id_info>
  <brief_title>Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases</brief_title>
  <acronym>ENCEPHALON</acronym>
  <official_title>Whole Brain Radiation Therapy (WBRT) Alone Versus Radiosurgery (SRS) for Patients With 1-10 Brain Metastases From Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juergen Debus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients suffering from small cell lung cancer (SCLC) are at high risk for developing brain
      metastases (BM). To prevent a clinical manifestation of preexisting microscopic brain
      dissemination, prophylactic cranial irradiation (PCI) is offered to both limited and
      extensive disease patients, if they respond to first line regime, thus being at risk or at
      chance to develop clinical brain metastases. However, up to 10-15% of patients present with
      BM at initial diagnosis. If MRI is used as a diagnostic tool for initial staging the number
      even increases up to 15-20%. Additionally, between 40 - 50% of patients develop BM until time
      of death and the risk of developing BM further increases with prolonged survival. Treatment
      options are usually limited to WBRT and palliative chemotherapy but the actual effect of
      therapeutic WBRT has mainly been studied in small retrospective and nonrandomized studies.
      WBRT has been established as the treatment standard in patients with cerebral metastases from
      SCLC, however, it has only modest efficacy. Results might be improved by additional dose
      escalation. A SRS to cerebral metastases may be indicated in patients with intracranial
      disease, and the current protocol is aimed at exploring the neurocognition and efficacy of
      SCLC in patients with brain metastases treated with SRS or WBRT.

      The present trial aims to exploratory investigate the treatment response to ´conventional
      whole brain radiotherapy´ (WBRT) and ´stereotactic radiotherapy´(SRS) in SCLC patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scientific Background: Patients suffering from BM from SCLC have a poor prognosis with a
      median survival ranging between 2-14 months. Treatment options for BM in SCLC are usually
      limited to WBRT, steroids or palliative chemotherapy. SCLC patients demonstrate an exception
      in the treatment of BM, because treatment options for a limited number of BM from other solid
      tumors commonly include surgery or SRS with or without WBRT. Even though SCLC is a
      radiosensitive tumor, higher doses are commonly not applied. Locally ablative treatments like
      SRS or surgery are less frequently used in patients with BM from SCLC as compared to other
      types of cancer due to the high incidence of brain metastases in SCLC and the increased
      likelihood of a diffuse failure pattern. It is of general belief that BM from SCLC are rarely
      solitary and usually occur at multiple sites. The investigators could not confirm these
      findings from this analysis as they found 1-5 BM in 39 % of their patients. WBRT, with a
      treatment time of about two weeks, is commonly the technique of choice for SCLC patients with
      any number of BM. In a recent Japanese trial, prophylactic cranial irradiation did not result
      in longer overall survival compared with observation in patients with early disease (ED)
      SCLC. PCI is therefore no longer recommended for patients with ED SCLC when patients receive
      regularly MRI examinations during follow-up.

      Though, the initial response to cranial irradiation is good, especially in the synchronous
      setting, SCLC patients are at high risk of developing intracranial recurrence. In the
      investigators´ retrospective analysis median Overall survival (OS) after re-WBRT was only 2
      months and the median OS after SRS was 6 months. These results are similar as compared to
      results for re-irradiation after PCI. In a recent analysis the investigators reported a
      prolonged survival for patients treated with SRS in the recurrent setting after previous PCI
      with a median survival of 5 months.

      Therefore, the number of patients with oligometastatic cerebral disease might rise. Based on
      recursive partitioning Analysis (RPA) classification, the investigators found a median
      survival after WBRT of 17 months in RPA class I, 7 months in class II and 3 months in class
      III (p&lt;0.0001), which is comparable to previous analyses using graded prognostic assessment
      (GPA) scoring. This is further of special interest as patients in RPA class I had a
      comparable or even better outcome than patients with non-cerebral disease treated with PCI.
      On the other hand, patients with RPA class III should be carefully selected for WBRT and
      treatment should be weighed against supportive therapy with steroids alone. This implicates
      that patient selection is mandatory, even in SCLC, and that the general paradigm of WBRT
      needs to be reevaluated.

      Trial Objectives: The purpose of this trial is to explore the neurocognitive response in
      patients with brain metastases from SCLC treated with WBRT or SRS. The investigators proposed
      that patients treated with SRS would have inferior neurocognitive function based on the
      Hopkins Verbal Learning Test-Revised (HVLT-R) compared with patients treated with SRS alone.

      Patients Selection: Patients with a diagnosis of brain metastases from SCLC will be evaluated
      and screened based on the protocol. All patients fulfilling the inclusion and exclusion
      criteria will be informed about the possibility to participate in the study. Registration for
      the study must be performed prior to beginning of RT. 56 patients will be enrolled in this
      exploratory clinical trial.

      Trial Design: This pilot trial will be conducted as a single-center prospective, randomized,
      two-arm Phase II study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognition</measure>
    <time_frame>3 month after treatment</time_frame>
    <description>Drop of at least 5 Points from baseline in HVLT-R test (Hopkins Verbal Learning Test-Revised)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intracranial progression</measure>
    <time_frame>up to 12 month after treatment</time_frame>
    <description>number of new cerebral metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial progression</measure>
    <time_frame>up to 12 month after treatment</time_frame>
    <description>Change in tumor size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 month OS</time_frame>
    <description>Duration of survival defined as the interval between the date of RT begin and the date of death or date of leaving the study e.g., lost to follow up) whatever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to brain metastases</measure>
    <time_frame>up to 12 month after treatment</time_frame>
    <description>Death which directly connects to existing brain metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locally progression-free survival</measure>
    <time_frame>up to 12 month after treatment</time_frame>
    <description>12 month Progression-fee survival referring to local tumour progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>12 month PFS</time_frame>
    <description>12 month Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in other cognitive performance measures</measure>
    <time_frame>up to 12 month after treatment</time_frame>
    <description>HVLT_R</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to 12 month after treatment</time_frame>
    <description>BN20 QoL Questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to 12 month after treatment</time_frame>
    <description>EORTC QoL Questionaire PAL (palliative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in other cognitive performance measures</measure>
    <time_frame>up to 12 month after treatment</time_frame>
    <description>CANTAB Test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>SCLC</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Arm A: SRS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receive stereotactic radiosurgery (SRS), dose prescription according to the size of radiated brain metastases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: WBRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive whole brain radiotherapy (WBRT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SRS</intervention_name>
    <description>For SRS the dose prescription to the PTV will be as follows:
20 Gy to the 70%-isodose (lesions &lt; 2 cm max. diameter)
18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)
6 x 5 Gy to the conformally surrounding isodose (lesions &gt; 3 cm max. diameter)</description>
    <arm_group_label>Arm A: SRS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>WBRT</intervention_name>
    <description>WBRT will be applied in 10 fractions with single doses of 3 Gy to the whole brain.</description>
    <arm_group_label>Arm B: WBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed small cell lung cancer (SCLC)

          -  Magentic resonance (MR)-imaging confirmed cerebral metastases (no resection, max.
             number of 10)

          -  age ≥ 18 years of Age

          -  For women with childbearing potential, (and men) adequate contraception.

          -  Ability of subject to understand character and individual consequences of the clinical
             trial

          -  Written informed consent (must be available before enrolment in the trial)

        Exclusion Criteria:

        refusal of the patients to take part in the study

          -  previous radiotherapy of the brain

          -  Patients who have not yet recovered from acute high-grade toxicities of prior
             therapies

          -  Known carcinoma &lt; 5 years ago (excluding Carcinoma in situ of the cervix, basal cell
             carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment
             interfering with study therapy

          -  Pregnant or lactating women

          -  Participation in another competing clinical study or observation period of competing
             trials, respectively

          -  MRI contraindication (i.e. cardiac pacemaker, implanted defibrillator, certain cardiac
             valve replacements, certain metal implants)

          -  Karnofsky score (KPS) &lt;60

          -  Simultaneous cytotoxic chemotherapy

          -  Last application of chemotherapy/immunotherapy/targeted therapy &lt;1 week before
             cerebral radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Rieken, PD.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>chief senior physician in the department of Radiation Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Rieken, PD. Dr.</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>8200</phone_ext>
    <email>stefan.rieken@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denise Bernhardt, Dr.</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>8200</phone_ext>
    <email>denise.bernhardt@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Heidelberg, Department of Radiation Oncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juergen Debus, Prof. Dr.Dr.</last_name>
      <phone>+49 6221 56</phone>
      <phone_ext>8200</phone_ext>
      <email>juergen.debus@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Rami El Shafie, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Paul, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006 Jun 7;295(21):2483-91.</citation>
    <PMID>16757720</PMID>
  </reference>
  <reference>
    <citation>Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999 Aug 12;341(7):476-84.</citation>
    <PMID>10441603</PMID>
  </reference>
  <reference>
    <citation>Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, Ten Haken RK, Yorke ED. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S3-9. doi: 10.1016/j.ijrobp.2009.09.040.</citation>
    <PMID>20171515</PMID>
  </reference>
  <reference>
    <citation>Bergqvist M, Brattström D, Bennmarker H, Wagenius G, Riska H, Brodin O. Irradiation of brain metastases from lung cancer: a retrospective study. Lung Cancer. 1998 Apr;20(1):57-63.</citation>
    <PMID>9699188</PMID>
  </reference>
  <reference>
    <citation>Bernhardt D, Adeberg S, Bozorgmehr F, Opfermann N, Hoerner-Rieber J, Repka MC, Kappes J, Thomas M, Bischoff H, Herth F, Heußel CP, Debus J, Steins M, Rieken S. Nine-year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small-cell Lung Cancer. Clin Lung Cancer. 2017 Jul;18(4):e267-e271. doi: 10.1016/j.cllc.2016.11.012. Epub 2016 Dec 2.</citation>
    <PMID>28027850</PMID>
  </reference>
  <reference>
    <citation>Bernhardt D, Adeberg S, Bozorgmehr F, Opfermann N, Hoerner-Rieber J, König L, Kappes J, Thomas M, Herth F, Heußel CP, Warth A, Debus J, Steins M, Rieken S. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. J Neurooncol. 2017 Aug;134(1):205-212. doi: 10.1007/s11060-017-2510-0. Epub 2017 May 30.</citation>
    <PMID>28560661</PMID>
  </reference>
  <reference>
    <citation>Bernhardt D, Bozorgmehr F, Adeberg S, Opfermann N, von Eiff D, Rieber J, Kappes J, Foerster R, König L, Thomas M, Debus J, Steins M, Rieken S. Outcome in patients with small cell lung cancer re-irradiated for brain metastases after prior prophylactic cranial irradiation. Lung Cancer. 2016 Nov;101:76-81. doi: 10.1016/j.lungcan.2016.09.010. Epub 2016 Sep 14.</citation>
    <PMID>27794411</PMID>
  </reference>
  <reference>
    <citation>van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007 Jun;16(3):219-42.</citation>
    <PMID>17621469</PMID>
  </reference>
  <reference>
    <citation>Carmichael J, Crane JM, Bunn PA, Glatstein E, Ihde DC. Results of therapeutic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys. 1988 Mar;14(3):455-9.</citation>
    <PMID>2830211</PMID>
  </reference>
  <reference>
    <citation>Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009 Nov;10(11):1037-44. doi: 10.1016/S1470-2045(09)70263-3. Epub 2009 Oct 2.</citation>
    <PMID>19801201</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1699-707.</citation>
    <PMID>4030437</PMID>
  </reference>
  <reference>
    <citation>Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51.</citation>
    <PMID>9128946</PMID>
  </reference>
  <reference>
    <citation>Giannone L, Johnson DH, Hande KR, Greco FA. Favorable prognosis of brain metastases in small cell lung cancer. Ann Intern Med. 1987 Mar;106(3):386-9.</citation>
    <PMID>3028222</PMID>
  </reference>
  <reference>
    <citation>Herfarth KK, Izwekowa O, Thilmann C, Pirzkall A, Delorme S, Hofmann U, Schadendorf D, Zierhut D, Wannenmacher M, Debus J. Linac-based radiosurgery of cerebral melanoma metastases. Analysis of 122 metastases treated in 64 patients. Strahlenther Onkol. 2003 Jun;179(6):366-71.</citation>
    <PMID>12789461</PMID>
  </reference>
  <reference>
    <citation>Hochstenbag MM, Twijnstra A, Wilmink JT, Wouters EF, ten Velde GP. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol. 2000 Jul;48(3):243-8.</citation>
    <PMID>11100822</PMID>
  </reference>
  <reference>
    <citation>Kochhar R, Frytak S, Shaw EG. Survival of patients with extensive small-cell lung cancer who have only brain metastases at initial diagnosis. Am J Clin Oncol. 1997 Apr;20(2):125-7.</citation>
    <PMID>9124183</PMID>
  </reference>
  <reference>
    <citation>Komaki R, Cox JD, Whitson W. Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. Cancer Treat Rep. 1981 Sep-Oct;65(9-10):811-4.</citation>
    <PMID>6268295</PMID>
  </reference>
  <reference>
    <citation>Lassen U, Kristjansen PE, Hansen HH. Brain metastases in small-cell lung cancer. Ann Oncol. 1995 Nov;6(9):941-4.</citation>
    <PMID>8624299</PMID>
  </reference>
  <reference>
    <citation>Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, Bentzen SM, Nam J, Deasy JO. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9. doi: 10.1016/j.ijrobp.2009.07.1754.</citation>
    <PMID>20171502</PMID>
  </reference>
  <reference>
    <citation>Newman SJ, Hansen HH. Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer. 1974 Feb;33(2):492-6.</citation>
    <PMID>4812766</PMID>
  </reference>
  <reference>
    <citation>Nugent JL, Bunn PA Jr, Matthews MJ, Ihde DC, Cohen MH, Gazdar A, Minna JD. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer. 1979 Nov;44(5):1885-93.</citation>
    <PMID>227582</PMID>
  </reference>
  <reference>
    <citation>Postmus PE. Brain Metastases From Small Cell Lung Cancer: Chemotherapy, Radiotherapy, or Both? Semin Radiat Oncol. 1995 Jan;5(1):69-73.</citation>
    <PMID>10717129</PMID>
  </reference>
  <reference>
    <citation>Quan AL, Videtic GM, Suh JH. Brain metastases in small cell lung cancer. Oncology (Williston Park). 2004 Jul;18(8):961-72; discussion 974, 979-80, 987. Review.</citation>
    <PMID>15328892</PMID>
  </reference>
  <reference>
    <citation>Scharp M, Hauswald H, Bischof M, Debus J, Combs SE. Re-irradiation in the treatment of patients with cerebral metastases of solid tumors: retrospective analysis. Radiat Oncol. 2014 Jan 3;9:4. doi: 10.1186/1748-717X-9-4.</citation>
    <PMID>24387239</PMID>
  </reference>
  <reference>
    <citation>Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, de Vries E. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur J Cancer. 2016 Jul;62:138-45. doi: 10.1016/j.ejca.2016.03.082. Epub 2016 May 26. Review.</citation>
    <PMID>27237360</PMID>
  </reference>
  <reference>
    <citation>Schwer AL, Gaspar LE. Update in the treatment of brain metastases from lung cancer. Clin Lung Cancer. 2006 Nov;8(3):180-6. Review.</citation>
    <PMID>17239293</PMID>
  </reference>
  <reference>
    <citation>Shibamoto Y, Baba F, Oda K, Hayashi S, Kokubo M, Ishihara S, Itoh Y, Ogino H, Koizumi M. Incidence of brain atrophy and decline in mini-mental state examination score after whole-brain radiotherapy in patients with brain metastases: a prospective study. Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1168-73. doi: 10.1016/j.ijrobp.2008.02.054. Epub 2008 May 19.</citation>
    <PMID>18495375</PMID>
  </reference>
  <reference>
    <citation>Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E, Senan S; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007 Aug 16;357(7):664-72.</citation>
    <PMID>17699816</PMID>
  </reference>
  <reference>
    <citation>Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Mueller RP, Tridello G, Collette L, Bottomley A. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013 Jan 1;31(1):65-72. doi: 10.1200/JCO.2011.41.0639. Epub 2012 Dec 3.</citation>
    <PMID>23213105</PMID>
  </reference>
  <reference>
    <citation>Son CH, Jimenez R, Niemierko A, Loeffler JS, Oh KS, Shih HA. Outcomes after whole brain reirradiation in patients with brain metastases. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e167-72. doi: 10.1016/j.ijrobp.2011.03.020. Epub 2011 May 27.</citation>
    <PMID>21620583</PMID>
  </reference>
  <reference>
    <citation>Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, Bhatt A, Jensen AW, Brown PD, Shih H, Kirkpatrick J, Schwer A, Gaspar LE, Fiveash JB, Chiang V, Knisely J, Sperduto CM, Mehta M. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):655-61. doi: 10.1016/j.ijrobp.2009.08.025. Epub 2009 Nov 26.</citation>
    <PMID>19942357</PMID>
  </reference>
  <reference>
    <citation>Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012 Feb 1;30(4):419-25. doi: 10.1200/JCO.2011.38.0527. Epub 2011 Dec 27.</citation>
    <PMID>22203767</PMID>
  </reference>
  <reference>
    <citation>Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, Nishio M, Kaneda H, Takayama K, Ishimoto O, Takeda K, Yoshioka H, Tachihara M, Sakai H, Goto K, Yamamoto N. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017 May;18(5):663-671. doi: 10.1016/S1470-2045(17)30230-9. Epub 2017 Mar 23.</citation>
    <PMID>28343976</PMID>
  </reference>
  <reference>
    <citation>Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, Xu W, Sahgal A. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003869. doi: 10.1002/14651858.CD003869.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Jan 25;1:CD003869.</citation>
    <PMID>22513917</PMID>
  </reference>
  <reference>
    <citation>Welzel G, Fleckenstein K, Schaefer J, Hermann B, Kraus-Tiefenbacher U, Mai SK, Wenz F. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1311-8. doi: 10.1016/j.ijrobp.2008.03.009. Epub 2008 Apr 28.</citation>
    <PMID>18448270</PMID>
  </reference>
  <reference>
    <citation>Wong WW, Schild SE, Sawyer TE, Shaw EG. Analysis of outcome in patients reirradiated for brain metastases. Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):585-90.</citation>
    <PMID>8621282</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Director of the Department Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>SCLC</keyword>
  <keyword>Brain Metastases</keyword>
  <keyword>SRS (stereotactic radiosurgery)</keyword>
  <keyword>WBRT (whole brain radiotherapy)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

